FindTrial
Sign In

Comparing the effect of adding Olanzapine versus Perphenazine on maintenance treatment of bipolar type I in outpatients referred to psychiatric clinic of Ahvaz Golestan Hospital in 2010

Comparing the effect of adding Olanzapine versus Perphenazine on maintenance treatment of bipolar type I in outpatients referred to psychiatric clinic

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201010315060N1
Enrollment
40
Registered
2011-09-25
Start date
2010-12-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mania. Mania without psychotic symptoms

Interventions

Intervention 1: First group takes 10-20 mg olanzapine for 6 weeks. Intervention 2: Second group takes 16-24 mg perphenazine for 6 weeks.
Treatment - Drugs
First group takes 10-20 mg olanzapine for 6 weeks.
Second group takes 16-24 mg perphenazine for 6 weeks.

Sponsors

Vice chancellor for Research, Ahvaz University of Medical science and Health Services
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Bipolar disorder diagnosis based on DSM-4-TR; Filling in the personal satisfaction form; Ages between 16-50 years; No Psychotic symptom. Exclusion criteria: Pregnancy; Organic disorders; Co morbidity; No tendency to admission; No ECT treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Decreasing extra pyramidal complications. Timepoint: weeks 0, 3 and 6. Method of measurement: Clinical examination.—

Primary

MeasureTime frame
Recovery rate based on n YMRS. Timepoint: in weeks 0, 3 & 6. Method of measurement: YMRS form.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Abbas Pezeshki

Ahvaz University of Medical Sciences and Health Services

dr.abbas.pezeshki@ajums.ac.ir , abbas.pezeshki@gmail.com , dr_abbas_pezeshki@yahoo.com+98 61 1374 3038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026